Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+ T cell recognition

JCI Insight

Volumn 1, Issue 7, 2016, Pages

  Tullett, Kirsteen M ^a,b,c   Leal Rojas, Ingrid M ^a   Minoda, Yoshihito ^a   Tan, Peck S ^b,c   Zhang, Jian Guo ^d,e   Smith, Corey ^f   Khanna, Rajiv ^f   Shortman, Ken ^d,e   Caminschi, Irina ^b,c,e   Lahoud, Mireille H ^b,c   Radford, Kristen J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BURNET INSTITUTE   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85070435549     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.87102     Document Type: Article

References (64)

1. Radford KJ, Tullett KM, Lahoud MH. Dendritic cells and cancer immunotherapy. Curr Opin Immunol. 2014;27:26-32.
2. Guilliams M, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. 2014;14(8):571-578.
3. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563-604.
4. Schlitzer A, Ginhoux F. Organization of the mouse and human DC network. Curr Opin Immunol. 2014;26:90-99.
5. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557-569.
6. + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207(6):1247-1260.
7. + dendritic cells. J Exp Med. 2010;207(6):1283-1292.
8. + dendritic cells. J Exp Med. 2010;207(6):1273-1281.
9. Chiang MC, et al. Differential uptake and cross-presentation of soluble and necrotic cell antigen by human DC subsets. Eur J Immunol. 2016;46(2):329-339.
10. Schulz O, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature. 2005;433(7028):887-892.
11. Kroczek RA, Henn V. The Role of XCR1 and its ligand XCL1 in antigen cross-presentation by murine and human dendritic cells. Front Immunol. 2012;3:14.
12. Caminschi I, et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood. 2008;112(8):3264-3273.
13. Sancho D, et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest. 2008;118(6):2098-2110.
14. + dendritic cells and a subset of monocytes. J Biol Chem. 2008;283(24):16693-16701.
15. Sancho D, et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature. 2009;458(7240):899-903.
16. Zhang J-G, et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity. 2012;36(4):646-657.
17. Zelenay S, et al. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. J Clin Invest. 2012;122(5):1615-1627.
18. Ahrens S, et al. F-Actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity. 2012;36(4):635-645.
19. Radford KJ, Caminschi I. New generation of dendritic cell vaccines. Hum Vaccin Immunother. 2013;9(2):259-264.
20. Broz ML, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(5):638-652.
21. Sanchez-Paulete AR, et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discovery. 2016;6(1):71-79.
22. Tullett KM, Lahoud MH, Radford KJ. Harnessing human cross-presenting CLEC9AXCR1 dendritic cells for immunotherapy. Front Immunol. 2014;5:239.
23. Tacken PJ, et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood. 2005;106(4):1278-1285.
24. + T cells by targeting antigens to human dendritic cells through DCIR. Blood. 2010;116(10):1685-1697.
25. Morse MA, et al. CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev Vaccines. 2011;10(6):733-742.
26. + myeloid dendritic cells. Blood. 2012;119(10):2284-2292.
27. Hawiger D, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194(6):769-779.
28. Bonifaz LC, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004;199(6):815-824.
29. + T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med. 2006;203(3):607-617.
30. Dudziak D, et al. Differential antigen processing by dendritic cell subsets in vivo. Science. 2007;315(5808):107-111.
31. Flynn BJ, et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A. 2011;108(17):7131-7136.
32. Dhodapkar MV, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014;6(232):232-251.
33. + dendritic cells at cross presentation. J Exp Med. 2013;210(5):1049-1063.
34. Kato M, et al. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int Immunol. 2006;18(6):857-869.
35. Lahoud MH, et al. Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype. J Immunol. 2011;187(2):842-850.
36. + T-cell compartment by antigen targeting to DNGR-1/CLEC9A. Eur J Immunol. 2010;40(5):1255-1265.
37. Idoyaga J, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to langerin, DEC205, and clec9a. Proc Natl Acad Sci U S A. 2011;108(6):2384-2389.
38. Kato Y, et al. Targeting antigen to Clec9A primes follicular Th cell memory responses capable of robust recall. J Immunol. 2015;195(3):1006-1014.
39. Iborra S, Izquierdo HM, Marinez-Lopez M, Blanco-Menendez N, Reis e Sousa C, Sancho D. The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice. J Clin Invest. 2012;122(5):1628-1643.
40. Li J, et al. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur J Immunol. 2015;45(3):854-864.
41. Corbett AJ, et al. Antigen delivery via two molecules on the CD8- dendritic cell subset induces humoral immunity in the absence of conventional “danger”. Eur J Immunol. 2005;35(10):2815-2825.
42. Flinsenberg TW, et al. Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation. J Virol. 2015;89(2):1058-1069.
43. + dendritic cells in vivo. J Immunol. 2014;192(4):1982-1989.
44. Newman R, et al. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees. Clin Immunol. 2001;98(2):164-174.
45. Reddy MP, et al. Eliminations of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antobody to human CD4. J Immunol. 2000;164(4):1925-1933.
46. + T cell responses with broad antigen specificity. J Immunol. 2011;186(2):1218-1227.
47. + T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A. 2007;104(4):1289-1294.
48. Gurer C, et al. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood. 2008;112(4):1231-1239.
49. Chatterjee B, et al. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood. 2012;120(10):2011-2020.
50. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol. 2008;9(5):558-566.
51. Mahnke K, et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol. 2000;151(3):673-683.
52. Petzold C, Schallenberg S, Stern JN, Kretschmer K. Targeted antigen delivery to DEC-205(+) dendritic cells for tolerogenic vaccination. Rev Diabet Stud. 2012;9(4):305-318.
53. + dendritic cell-targeted tolerogenic vaccination promotes immune tolerance in experimental autoimmune arthritis. J Immunol. 2015;194(10):4804-4813.
54. Ring S, Maas M, Nettelbeck DM, Enk AH, Mahnke K. Targeting of autoantigens to DEC205(+) dendritic cells in vivo suppresses experimental allergic encephalomyelitis in mice. J Immunol. 2013;191(6):2938-2947.
55. Witmer-Pack MD, Swiggard WJ, Mirza A, Inaba K, Steinman RM. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. Cell Immunol. 1995;163(1):157-162.
56. Swiggard WJ, Mirza A, Nussenzweig M, Steinman RM. DEC-205, a 205-kDa protein abundant on mouse dendritic cells and thymic epithelium that is detected by the monoclonal antibodyNLDC-145: purification, characterization, and N-terminal amino acid sequence. Cell Immunol. 1995;165(2):302-311.
57. Hartung E, et al. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1. J Immunol. 2015;194(3):1069-1079.
58. + T-cell responses against influenza virus. Eur J Immunol. 2015;45(2):624-635.
59. Kontermann R, Duebel S, eds. Antibody Engineering. Vol. 1. Berlin/Heidelberg, Germany: Springer-Verlag; 2010.
60. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies. mAbs. 2010;2(3):256-265.
61. Hersey P, Gallagher S. A focus on PD-L1 in human melanoma. Clin Cancer Res. 2013;19(3):514-516.
62. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450-461.
63. Lahoud MH, et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci U S A. 2012;109(40):16270-16275.
64. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol. 2000;164(6):2978-2986.